BioCorteX Ltd is a limited company (Ltd) registered in England and Wales with registration number 13287534. The company was established on March 23, 2021, and currently maintains an active status. Its registered address is 167-169 Great Portland Street, London, W1W 5PF. The company’s primary industry, as defined by the Standard Industrial Classification (SIC 72110), is listed as “None.” BioCorteX specializes in research and experimental development on biotechnology. Based on website information, the company’s size is described as “N/A,” indicating it is a research and experimental development company. Its key focus is on capturing the human-bacterial relationship to determine drug efficacy for individual patients. The company’s website indicates no services are offered and no information is available regarding international presence or hiring activities. Financial records show accounts were prepared as of March 31, 2024, with charges being false and the company not insolvent. The company holds a Skilled Worker visa, with a worker rating of ‘A’. This suggests a positive assessment of the applicant’s skills and experience. The company’s stated mission centers around addressing the challenge of predicting drug effectiveness based on individual patient characteristics, leveraging the complex interaction between humans and their microbiome.

BioCorteX Ltd is a limited company (Ltd) registered in England and Wales with registration number 13287534. The company was established on March 23, 2021, and currently maintains an active status. Its registered address is 167-169 Great Portland Street, London, W1W 5PF. The company’s primary industry, as defined by the Standard Industrial Classification (SIC 72110), is listed as “None.” BioCorteX specializes in research and experimental development on biotechnology. Based on website information, the company’s size is described as “N/A,” indicating it is a research and experimental development company. Its key focus is on capturing the human-bacterial relationship to determine drug efficacy for individual patients. The company’s website indicates no services are offered and no information is available regarding international presence or hiring activities. Financial records show accounts were prepared as of March 31, 2024, with charges being false and the company not insolvent. The company holds a Skilled Worker visa, with a worker rating of ‘A’. This suggests a positive assessment of the applicant’s skills and experience. The company’s stated mission centers around addressing the challenge of predicting drug effectiveness based on individual patient characteristics, leveraging the complex interaction between humans and their microbiome.